Pegylated interferon fractal pharmacokinetics: Individualized dosing for hepatitis c virus infection

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 3, 2013, Pages 1115-1120

  Jain, Mamta K ^a   Pasipanodya, Jotam G ^a   Alder, Lara ^a   Lee, William M ^a   Gumbo, Tawanda ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG CLEARANCE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MALE; MICROBIOLOGICAL PARAMETERS; PREDICTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIRUS LOAD;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIVIRAL AGENTS; AREA UNDER CURVE; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; DRUG THERAPY, COMBINATION; FEMALE; FRACTALS; HEPACIVIRUS; HEPATITIS C; HUMANS; INDIVIDUALIZED MEDICINE; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; REGRESSION ANALYSIS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84874078862     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02208-12     Document Type: Article

References (30)

1. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Advance Study Team. 2011. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364:2405-2416.
2. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki J-P. 2011. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364: 1195-1206.
3. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F. 2011. Response- guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med. 365:1014 -1024.
4. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin C, Weegink C, Reesink H, Zeuzem S, Kwong AD. 2007. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132:1767-1777.
5. Susser S, Welsch C, Wang Y, Zettler M, Domingues FS, Karey U, Hughes E, Ralston R, Tong X, Herrmann E, Zeuzem S, Sarrazin C. 2009. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 50:1709 -1718.
6. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, Rustgi V, McPhee F, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DI, Eley T, Guo T, Grasela DM, Pasquinelli C. 2012. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 366:216 -224.
7. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401.
8. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG. 2010. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 139:120 -129.
9. Neely M, Jelliffe R. 2010. Practical, individualized dosing: 21st century therapeutics and the clinical pharmacometrician. J. Clin. Pharmacol. 50: 842-847.
10. Kleiber M. 1932. Body size and metabolism. Hilgardia 6:315-353.
11. Mandelbrot B. 1982. The fractal geometry of nature.WHFreeman & Co, New York, NY.
12. West GB, Brown JH, Enquist BJ. 1997. A general model for the origin of allometric scaling laws in biology. Science 276:122-126.
13. West GB, Brown JH, Enquist BJ. 1999. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 284:1677- 1679.
14. Liao XW, Ling Y, Li XH, Han Y, Zhang SY, Gu LL, Yu DM, Yao BL, Zhang DH, Jin GD, Lu ZM, Gong QM, Zhang XX. 2011. Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population. Antivir. Ther. 16:141-147.
15. Biomedical Stimulation Resource. 2009. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulation Resource, Los Angeles, CA.
16. Akaike H. 1974. A new look at the statistical model identification. IEEE Trans. Automated Control. 19:716 -723.
17. Ludden TM, Beal SL, Sheiner LB. 1994. Comparison of the Akaike information criterion, the Schwarz criterion and the F test as guides to model selection. J. Pharmacokinet. Biopharm. 22:431- 445.
18. Schwarz G. 1978. Estimating the dimension of a model. Ann. Statist. 6:461- 464.
19. Breiman L, Friedman JH, Olshen RA, Stone CJ. 1984. Classification and regressions trees. Wadsworth, Belmont, CA.
20. Steinberg D, Colla P. 1995. CART: tree-structured non-parametric data analysis. Salford Systems, San Diego, CA.
21. Hall RG, Swancutt MA, Gumbo T. 2011. Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people. Antimicrob. Agents Chemother. 55:5107-5112.
22. Hall RG, II, Swancutt MA, Meek C, Leff RD, Gumbo T. 2012. Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people. Antimicrob. Agents Chemother. 56: 1502-1507.
23. Bressler BL, Guindi M, Tomlinson G, Heathcote J. 2003. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 38:639-644.
24. Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallee M, Heaton S, Conrad A, Pockros PJ, McHutchison JG. 2004. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J. Hepatol. 40:484-490.
25. Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, Powell EE. 2006. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 55:529 -535.
26. Pattullo V, Ravindran NC, Mazzulli T, Wong DK, Heathcote EJ. 2010. Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C. J. Viral Hepat. 17: 834-838.
27. Reddy KR, Shiffman ML, Rodriguez-Torres M, Cheinquer H, Abdurakhmanov D, Bakulin I, Morozov V, Silva GF, Geyvandova N, Stanciu C, Rabbia M, McKenna M, Thommes JA, Harrison SA. 2010. Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads. Gastroenterology 139:1972-1983.
28. de Araujo ES, Dahari H, Cotler SJ, Layden TJ, Neumann AU, Melo CE, Barone AA. 2011. Pharmacodynamics of PEG-IFN-α-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients. J. Acquir. Immune Defic. Syndr. 56:95-99.
29. Howell CD, Dowling TC, Paul M, Wahed AS, Terrault NA, Taylor M, Jeffers L, Hoofnagle JH. 2008. Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection. Clin. Gastroenterol. Hepatol. 6:575-583.
30. Shudo E, Ribeiro RM, Perelson AS. 2009. Modeling HCV kinetics under therapy using PK andPDinformation. Expert Opin. Drug Metab. Toxicol. 5:321-332.